patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_580754 | REC_0010701 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 16.5 | 78 | female | 2 | 11 | 5.5 | 5 | sotorasib 960 mg daily | 5.2 | false | MSI-H | 2026-03-15T05:35:59.528311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451258 | REC_0010702 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 16.9 | 68 | female | 1 | 10 | 7.1 | 3 | sotorasib 960 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:59.528550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122958 | REC_0010703 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13 | 68 | female | 0 | 21 | 4.8 | 5 | entrectinib 600 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:35:59.528818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877650 | REC_0010704 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 9.8 | 72 | female | 1 | 3 | 5.3 | 6 | alectinib 600 mg BID | 10.7 | true | MSS | 2026-03-15T05:35:59.529050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403290 | REC_0010705 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 16.5 | 59 | male | 0 | 12 | 6.3 | 2 | sotorasib 960 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:59.529288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684373 | REC_0010706 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 16.2 | 74 | female | 1 | 18 | 5.2 | 1 | entrectinib 600 mg daily | 28.8 | false | MSS | 2026-03-15T05:35:59.529532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210584 | REC_0010707 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 9.3 | 64 | male | 1 | 22 | 4.7 | 6 | sotorasib 960 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:59.529797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_353890 | REC_0010708 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 16 | 17.4 | 67 | female | 0 | 20 | 5.6 | 6 | pembrolizumab 200 mg q3w | 12.8 | false | MSI-H | 2026-03-15T05:35:59.530043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151337 | REC_0010709 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.2 | 73 | female | 2 | 13 | 5.8 | 6 | entrectinib 600 mg daily | 4.7 | true | MSS | 2026-03-15T05:35:59.530318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673086 | REC_0010710 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 14.6 | 70 | female | 2 | 7 | 5.1 | 2 | osimertinib 80 mg daily | 34.3 | true | MSI-H | 2026-03-15T05:35:59.530568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707115 | REC_0010711 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 13.3 | 45 | female | 0 | 20 | 4.2 | 5 | pembrolizumab 200 mg q3w | 10.5 | true | MSS | 2026-03-15T05:35:59.530818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152249 | REC_0010712 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 16.9 | 62 | male | 0 | 14 | 4.1 | 5 | osimertinib 80 mg daily | 6.4 | false | MSS | 2026-03-15T05:35:59.531062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260950 | REC_0010713 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 14.6 | 73 | female | 3 | 1 | 5.5 | 1 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:59.531505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907309 | REC_0010714 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 8.1 | 77 | female | 2 | 15 | 7.5 | 3 | alectinib 600 mg BID | 14.7 | false | MSS | 2026-03-15T05:35:59.531921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554076 | REC_0010715 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.2 | 55 | male | 0 | 18 | 5.1 | 6 | entrectinib 600 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:35:59.532221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191016 | REC_0010716 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 19.6 | 64 | male | 0 | 14 | 6 | 7 | pembrolizumab 200 mg q3w | 14.4 | false | MSI-H | 2026-03-15T05:35:59.532493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575870 | REC_0010717 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 26 | 6 | 73 | female | 2 | 15 | 5.9 | 0 | pembrolizumab 200 mg q3w | 53.3 | false | MSS | 2026-03-15T05:35:59.532742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754635 | REC_0010718 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 6.9 | 68 | female | 0 | 17 | 6.2 | 1 | alectinib 600 mg BID | 19.8 | true | MSS | 2026-03-15T05:35:59.532984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514146 | REC_0010719 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 6.7 | 62 | male | 1 | 26 | 3.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 38.6 | false | MSS | 2026-03-15T05:35:59.533226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333464 | REC_0010720 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.2 | 80 | female | 1 | 12 | 6.7 | 5 | pembrolizumab 200 mg q3w | 9.8 | true | MSS | 2026-03-15T05:35:59.533481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334682 | REC_0010721 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.5 | 72 | female | 1 | 14 | 5.8 | 4 | alectinib 600 mg BID | 12 | true | MSI-H | 2026-03-15T05:35:59.533744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984681 | REC_0010722 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 27 | 5 | 73 | female | 0 | 16 | 7.1 | 0 | entrectinib 600 mg daily | 30 | false | MSS | 2026-03-15T05:35:59.534000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416657 | REC_0010723 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 11.3 | 75 | male | 1 | 24 | 6.6 | 1 | osimertinib 80 mg daily | 19.2 | true | MSI-H | 2026-03-15T05:35:59.534261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987152 | REC_0010724 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 3.9 | 64 | male | 1 | 41 | 5.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 4.5 | true | MSS | 2026-03-15T05:35:59.534525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213630 | REC_0010725 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 2.9 | 77 | female | 3 | 22 | 3.6 | 3 | entrectinib 600 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.534782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740676 | REC_0010726 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.4 | 83 | female | 2 | 13 | 8.7 | 4 | pembrolizumab 200 mg q3w | 10.5 | true | MSS | 2026-03-15T05:35:59.535198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175544 | REC_0010727 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.9 | 66 | female | 1 | 20 | 6.7 | 2 | osimertinib 80 mg daily | 18.9 | false | MSS | 2026-03-15T05:35:59.535495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434374 | REC_0010728 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 10.9 | 82 | female | 1 | 19 | 6.1 | 6 | sotorasib 960 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:59.535740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585013 | REC_0010729 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 11.6 | 73 | female | 1 | 22 | 6.7 | 6 | osimertinib 80 mg daily | 6.3 | true | MSI-H | 2026-03-15T05:35:59.535982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859459 | REC_0010730 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 14.1 | 60 | male | 0 | 18 | 4.5 | 1 | pembrolizumab 200 mg q3w | 18.7 | false | MSS | 2026-03-15T05:35:59.536283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927186 | REC_0010731 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 5.6 | 70 | male | 1 | 15 | 6.1 | 1 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:59.536535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885779 | REC_0010732 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 24 | 7.7 | 69 | female | 0 | 21 | 7.2 | 0 | osimertinib 80 mg daily | 19.2 | false | MSS | 2026-03-15T05:35:59.536768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864569 | REC_0010733 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 17.1 | 82 | female | 2 | 19 | 4.8 | 3 | alectinib 600 mg BID | 7.5 | true | MSI-H | 2026-03-15T05:35:59.537000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994292 | REC_0010734 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 5 | 57 | male | 0 | 23 | 6.2 | 2 | osimertinib 80 mg daily | 21.7 | false | MSS | 2026-03-15T05:35:59.537234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381970 | REC_0010735 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 11.5 | 68 | female | 1 | 12 | 4.4 | 1 | sotorasib 960 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:35:59.537467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899865 | REC_0010736 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12.1 | 63 | female | 1 | 22 | 7.4 | 4 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:59.537706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954306 | REC_0010737 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 5.2 | 63 | female | 1 | 62 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:59.537939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203573 | REC_0010738 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.9 | 79 | female | 2 | 13 | 7.5 | 5 | alectinib 600 mg BID | 17.5 | true | MSS | 2026-03-15T05:35:59.538173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915667 | REC_0010739 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 3.3 | 54 | male | 0 | 20 | 5 | 1 | pembrolizumab 200 mg q3w | 24.9 | true | MSS | 2026-03-15T05:35:59.538507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643221 | REC_0010740 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 15.1 | 79 | female | 1 | 11 | 5.5 | 7 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:59.538752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749299 | REC_0010741 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 35 | 9.4 | 68 | male | 1 | 63 | 6.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 28 | true | MSS | 2026-03-15T05:35:59.539000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210805 | REC_0010742 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 34 | 6.8 | 65 | male | 0 | 59 | 3 | 7 | pembrolizumab 200 mg q3w | 9.2 | false | MSS | 2026-03-15T05:35:59.539251+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586274 | REC_0010743 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4.2 | 68 | female | 0 | 47 | 5 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.1 | false | MSS | 2026-03-15T05:35:59.539490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638374 | REC_0010744 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13.9 | 74 | female | 1 | 12 | 7.3 | 3 | osimertinib 80 mg daily | 23.9 | true | MSS | 2026-03-15T05:35:59.539728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435389 | REC_0010745 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 29 | 9.8 | 67 | female | 1 | 24 | 6.3 | 0 | osimertinib 80 mg daily | 53.9 | false | MSS | 2026-03-15T05:35:59.539968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354366 | REC_0010746 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 13.4 | 53 | male | 0 | 10 | 5 | 8 | alectinib 600 mg BID | 8.6 | true | MSS | 2026-03-15T05:35:59.540250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730568 | REC_0010747 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 14.3 | 72 | female | 0 | 24 | 4.2 | 5 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:59.540488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706806 | REC_0010748 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 17.1 | 79 | female | 1 | 9 | 3.3 | 8 | sotorasib 960 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:59.540726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279230 | REC_0010749 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.3 | 63 | female | 1 | 59 | 4.5 | 4 | pembrolizumab 200 mg q3w | 14.8 | false | MSS | 2026-03-15T05:35:59.540959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941375 | REC_0010750 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 14.8 | 70 | female | 1 | 23 | 7.1 | 5 | alectinib 600 mg BID | 18.2 | true | MSI-H | 2026-03-15T05:35:59.541193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606486 | REC_0010751 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.8 | 67 | female | 1 | 11 | 6.2 | 5 | entrectinib 600 mg daily | 6.8 | false | MSI-H | 2026-03-15T05:35:59.541431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347320 | REC_0010752 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 1.5 | 79 | male | 1 | 4 | 7.1 | 5 | entrectinib 600 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:59.541788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803415 | REC_0010753 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 11.3 | 64 | male | 1 | 23 | 5.3 | 4 | sotorasib 960 mg daily | 6.9 | true | MSI-H | 2026-03-15T05:35:59.542054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305333 | REC_0010754 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.4 | 66 | female | 1 | 17 | 4.3 | 8 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:59.542297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488691 | REC_0010755 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.9 | 67 | female | 0 | 12 | 3.1 | 7 | osimertinib 80 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:59.542535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554691 | REC_0010756 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.6 | 72 | male | 1 | 21 | 7.7 | 7 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:59.542778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295120 | REC_0010757 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.6 | 69 | female | 0 | 17 | 6.8 | 5 | pembrolizumab 200 mg q3w | 8 | false | MSS | 2026-03-15T05:35:59.543030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762885 | REC_0010758 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.8 | 77 | female | 0 | 43 | 5 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.2 | false | MSS | 2026-03-15T05:35:59.543317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562479 | REC_0010759 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.1 | 58 | male | 0 | 11 | 6 | 1 | sotorasib 960 mg daily | 22.1 | false | MSS | 2026-03-15T05:35:59.543621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553891 | REC_0010760 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 11.7 | 72 | female | 2 | 19 | 5.9 | 4 | osimertinib 80 mg daily | 8.1 | false | MSS | 2026-03-15T05:35:59.543907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319225 | REC_0010761 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 14.4 | 62 | female | 1 | 20 | 2.6 | 1 | pembrolizumab 200 mg q3w | 25.6 | true | MSS | 2026-03-15T05:35:59.544216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310833 | REC_0010762 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 8.7 | 71 | female | 0 | 17 | 5.7 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:59.544490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235037 | REC_0010763 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 12.7 | 54 | male | 0 | 20 | 7 | 2 | entrectinib 600 mg daily | 34.2 | false | MSI-H | 2026-03-15T05:35:59.544750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788625 | REC_0010764 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 31 | 6.3 | 70 | male | 2 | 15 | 3.5 | 2 | pembrolizumab 200 mg q3w | 15.4 | true | MSS | 2026-03-15T05:35:59.545001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107627 | REC_0010765 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 8.6 | 67 | female | 1 | 9 | 5.9 | 4 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:35:59.545361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714880 | REC_0010766 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 9.7 | 68 | male | 0 | 13 | 7.2 | 4 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:59.545604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443133 | REC_0010767 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.6 | 65 | female | 1 | 63 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.3 | false | MSS | 2026-03-15T05:35:59.545840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286032 | REC_0010768 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 12.7 | 75 | female | 2 | 20 | 4.4 | 3 | alectinib 600 mg BID | 7.8 | true | MSS | 2026-03-15T05:35:59.546082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139654 | REC_0010769 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 10 | 61 | female | 0 | 10 | 5.3 | 0 | osimertinib 80 mg daily | 47.3 | true | MSS | 2026-03-15T05:35:59.546320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_834754 | REC_0010770 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6 | 62 | male | 0 | 58 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:35:59.546551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221657 | REC_0010771 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 35 | 14 | 75 | female | 2 | 13 | 4.1 | 0 | osimertinib 80 mg daily | 27.6 | false | MSS | 2026-03-15T05:35:59.546783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532663 | REC_0010772 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 18.3 | 64 | male | 0 | 23 | 4.9 | 4 | osimertinib 80 mg daily | 7.6 | true | MSI-H | 2026-03-15T05:35:59.547015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214782 | REC_0010773 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 15.6 | 72 | male | 2 | 6 | 6.1 | 2 | sotorasib 960 mg daily | 28.3 | true | MSS | 2026-03-15T05:35:59.547250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849547 | REC_0010774 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 3.3 | 62 | male | 1 | 17 | 7.2 | 1 | entrectinib 600 mg daily | 27.9 | false | MSS | 2026-03-15T05:35:59.547481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302536 | REC_0010775 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.6 | 63 | female | 1 | 24 | 6.7 | 5 | alectinib 600 mg BID | 11.1 | false | MSS | 2026-03-15T05:35:59.547712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213401 | REC_0010776 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 16.4 | 65 | female | 1 | 4 | 6.7 | 1 | osimertinib 80 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:59.547949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586032 | REC_0010777 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 11 | 58 | male | 0 | 15 | 5.7 | 4 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:59.548266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708029 | REC_0010778 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 11.1 | 68 | female | 1 | 8 | 6.5 | 0 | pembrolizumab 200 mg q3w | 9.7 | true | MSS | 2026-03-15T05:35:59.548568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668297 | REC_0010779 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.3 | 57 | female | 1 | 51 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.8 | false | MSS | 2026-03-15T05:35:59.548805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101037 | REC_0010780 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7.5 | 71 | female | 3 | 18 | 6.4 | 5 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:59.549037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953922 | REC_0010781 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 17.1 | 55 | male | 0 | 19 | 6.3 | 6 | osimertinib 80 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:59.549273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843159 | REC_0010782 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.3 | 74 | male | 3 | 41 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:59.549505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790322 | REC_0010783 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 36 | 17.1 | 64 | male | 1 | 22 | 4.7 | 3 | alectinib 600 mg BID | 27.7 | true | MSI-H | 2026-03-15T05:35:59.549741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267134 | REC_0010784 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 13.2 | 83 | female | 2 | 13 | 7.7 | 2 | entrectinib 600 mg daily | 16.6 | true | MSI-H | 2026-03-15T05:35:59.549972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113989 | REC_0010785 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 15 | 4.8 | 68 | female | 1 | 9 | 4.3 | 1 | osimertinib 80 mg daily | 21 | true | MSS | 2026-03-15T05:35:59.550204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960295 | REC_0010786 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.4 | 57 | female | 1 | 19 | 3.3 | 6 | entrectinib 600 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:35:59.550438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620004 | REC_0010787 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 11 | 72 | female | 1 | 8 | 5.5 | 2 | alectinib 600 mg BID | 21.1 | false | MSS | 2026-03-15T05:35:59.550677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657217 | REC_0010788 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 8.4 | 55 | male | 1 | 9 | 2.8 | 2 | entrectinib 600 mg daily | 23.1 | true | MSS | 2026-03-15T05:35:59.550907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391892 | REC_0010789 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 36 | 16.3 | 69 | female | 0 | 18 | 5.7 | 1 | entrectinib 600 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:59.551138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768284 | REC_0010790 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 14.5 | 62 | male | 1 | 1 | 4.7 | 2 | alectinib 600 mg BID | 21.6 | false | MSS | 2026-03-15T05:35:59.551373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166883 | REC_0010791 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.9 | 52 | male | 0 | 70 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.4 | true | MSS | 2026-03-15T05:35:59.551652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702107 | REC_0010792 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.5 | 57 | female | 0 | 23 | 3.4 | 6 | osimertinib 80 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:59.551908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127558 | REC_0010793 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 5.3 | 65 | female | 1 | 12 | 6.2 | 6 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:35:59.552199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130835 | REC_0010794 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.2 | 68 | female | 1 | 10 | 3.9 | 1 | alectinib 600 mg BID | 17.6 | false | MSI-H | 2026-03-15T05:35:59.552455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389517 | REC_0010795 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.6 | 74 | female | 2 | 5 | 5 | 1 | osimertinib 80 mg daily | 19.4 | true | MSS | 2026-03-15T05:35:59.552705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586627 | REC_0010796 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 14.2 | 71 | male | 1 | 16 | 4.8 | 2 | alectinib 600 mg BID | 19.9 | true | MSS | 2026-03-15T05:35:59.552986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546717 | REC_0010797 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 5.8 | 57 | female | 0 | 47 | 6.5 | 6 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:59.553238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740574 | REC_0010798 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 9.5 | 85 | female | 2 | 13 | 7.4 | 6 | pembrolizumab 200 mg q3w | 13.8 | true | MSS | 2026-03-15T05:35:59.553512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703640 | REC_0010799 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 10.4 | 71 | female | 2 | 13 | 5.6 | 1 | alectinib 600 mg BID | 12.7 | false | MSI-H | 2026-03-15T05:35:59.553775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900595 | REC_0010800 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 8.4 | 66 | female | 1 | 7 | 4.3 | 1 | alectinib 600 mg BID | 18.9 | false | MSS | 2026-03-15T05:35:59.554038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.